CymaBay Therapeutics, Inc.
CBAY
Classificação em ações
#5833
CymaBay Therapeutics, Inc. is a biopharmaceutical company in the clinical... CymaBay Therapeutics, Inc. is a biopharmaceutical company in the clinical development phase, focused on discovering and delivering treatments for liver disorders and various other long-term illnesses. A key experimental therapy in their portfolio is seladelpar (MBX-8025), a selective activator of the peroxisome proliferator activated receptor delta. This compound is currently undergoing a pivotal Phase III clinical trial for primary biliary cholangitis (PBC), and has also concluded a Phase 2b study investigating its use for nonalcoholic steatohepatitis (NASH). Additionally, the company is advancing MBX-2982 through Phase 2a clinical trials, aiming to address hypoglycemia in individuals with type 1 diabetes. CymaBay maintains strategic partnerships, including a licensing arrangement with ABW Cyclops SPV LP to aid the development of seladelpar for PBC. They also possess a global license from Janssen Pharmaceuticals, Inc. to research, develop, and bring to market compounds active against an undisclosed metabolic disease target. Established in 1988 and formerly known as Metabolex, Inc., CymaBay Therapeutics, Inc. is headquartered in Newark, California.
Preço da ação
$32.48
Última sincronização: 2024-03-25
Valor de mercado
$2.24B
Variação (1 dia)
0.00%
Variação (1 ano)
-0.01%
País
US
Negociar CymaBay Therapeutics, Inc. (CBAY)
Categoria
Healthcare
Capitalização de mercado de CymaBay Therapeutics, Inc.(CBAY)
Valor de mercado: $2.24B
Em October 2026, CymaBay Therapeutics, Inc. tem uma capitalização de mercado de $2.24B. Isso faz com que CymaBay Therapeutics, Inc. seja a 5833rd empresa mais valiosa do mundo em termos de capitalização de mercado, de acordo com os nossos dados. A capitalização de mercado, também chamada de market cap, é o valor total de mercado das ações em circulação de uma empresa de capital aberto e é amplamente utilizada para medir o valor de uma empresa.
Histórico de capitalização de mercado de CymaBay Therapeutics, Inc. de 2018 a 2026
CBAY comparado com o topo de 5 mais populares stocks
